{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Gomes MB"],"pubmed_abstract":["<h4>Background</h4>To evaluate the real-world care of Brazilian individuals with type 1 diabetes (T1D).<h4>Methods</h4>The Brazilian Type 1 Diabetes Study Group (BrazDiab1SG), was conducted in two waves, in all Brazilian geographical regions. The first enrolled 3,591 individuals with data obtained from medical records. The second evaluated 1,760 individuals with laboratory and genetic data performed at State University of Rio de Janeiro.<h4>Results</h4>In the first and second waves, the average HbA1c was 9.3% and 9.0%, HbA1c above 10%, 32.2% and 26.3%, and individuals with HbA1c < 7.0%, 13.2% and 13.5%, respectively. Intermediate/long plus short acting insulins was the commonest used treatment modality. Less than 30% of the individuals achieved good glycemic control. Individuals in pumps a"],"journal":["Diabetology & metabolic syndrome"],"pagination":["166"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12102832"],"repository":["biostudies-literature"],"pubmed_title":["Type 1 diabetes in Brazil: a narrative overview of the Brazilian Type 1 Diabetes Study Group."],"pmcid":["PMC12102832"],"pubmed_authors":["Mallmann F","Melo NH","Mendes ADN","Cobas R","Fonseca RMC","Takano C","Gomes MB","Sampaio E","Dib SA","Tannus LRM","de Oliveira JEP","Dualib P","Rea RR","de Fatima Guedes M","Canani LH","Sepulveda J","Brazilian Diabetes Study Group","Costa E Forti A","Porto LC","Facanha C","de Araujo NBC","da Silva SC","Drumond KG","Pinheiro A","Azulay R","Mattos T","Luescher JL","Berardo RS","Melo LN","Morales PH","Rodacki M","Silva D","Jezini DL","Correa-Giannella MLC","Malerbi F","Romanzini NB","Calliari L","Lavigne S","Rassi N","Kasprowicz R","Fonseca LC","Azevedo M","Faria M","Tolentino M","Leal FS","Nery M","Dantas JR","de Almeida Faria ACR","Zajdenverg L","Admoni SN","Fernandes VO","de Camargo Sallum Filho CF","Coral M","Pires AC","Manna TD","Rezende KF","Ferreira L","Foss MC","Pavin EJ","Dos Santos DP","Junior RM","Aguiar CH","Felicio JS","Montenegro AP","de Araujo LA","de Almeida HG","Salvodelli R","Ramos A","Pedrosa HC","Santos FM","Negrato CA","Tschiedel B"],"additional_accession":[]},"is_claimable":false,"name":"Type 1 diabetes in Brazil: a narrative overview of the Brazilian Type 1 Diabetes Study Group.","description":"<h4>Background</h4>To evaluate the real-world care of Brazilian individuals with type 1 diabetes (T1D).<h4>Methods</h4>The Brazilian Type 1 Diabetes Study Group (BrazDiab1SG), was conducted in two waves, in all Brazilian geographical regions. The first enrolled 3,591 individuals with data obtained from medical records. The second evaluated 1,760 individuals with laboratory and genetic data performed at State University of Rio de Janeiro.<h4>Results</h4>In the first and second waves, the average HbA1c was 9.3% and 9.0%, HbA1c above 10%, 32.2% and 26.3%, and individuals with HbA1c < 7.0%, 13.2% and 13.5%, respectively. Intermediate/long plus short acting insulins was the commonest used treatment modality. Less than 30% of the individuals achieved good glycemic control. Individuals in pumps a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-01T11:46:10.528Z","creation":"2025-08-23T03:09:21.691Z"},"accession":"S-EPMC12102832","cross_references":{"pubmed":["40410767"],"doi":["10.1186/s13098-025-01708-6"]}}